GreenLight is a bio-performance company with a unique, cell-free production platform that delivers high-performing RNA solutions to human, plant, and animal challenges.
GreenLight develops RNA products for plant and life science applications, and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, and plant protection.
GreenLight Biosciences was founded in 2009 by Andrey J. Zarur & Marta Ortega-Valle. The company is headquartered in Medford, MA, with Plant Sciences R&D operations in RTP, NC and St. Louis, MO.
GreenLight Biosciences is dedicated to bringing its proprietary, cell-free bioprocessing method to market and produce low-cost, high-quality RNA in a safe and environmentally friendly manner. The company's goal is to commercialize products to improve plant and human health, and help our partners research and create natural RNA-based products.
GreenLight's platform is uniquely capable of producing RNA sequences of exceptional fidelity, in a fully-scalable fashion, and at a lower cost than any other production platforms. The team at GreenLight is focused on the discovery and development of RNA-based products for agriculture and human health.
GreenLight Biosciences is backed by S2G Ventures, Baird Capital, Blue I/O, Continental Grain Company, Tao Capital Partners, Alexandria Venture Investments and others. The company raised $17M in a new round of funding on May 12, 2020. This brings GreenLight's total funding to $113M to date.